CanPath data sheds light on air pollution’s hidden role in rheumatic disease

Air pollution isn’t just a lung issue. It has far-reaching effects on immune function and autoimmune diseases. CanPath’s vast dataset offers researchers a unique opportunity to explore these connections and advance air pollution and autoimmune disease research. Air pollution is often associated with respiratory conditions, but emerging research reveals its impact extends beyond the lungs, influencing immune system function and contributing to autoimmune and rheumatic diseases. Understanding these connections is critical for disease prevention, treatment, and public health strategies. Dr. Sasha Bernatsky, a rheumatologist and epidemiologist, has been at the forefront of this research. Her work highlights how air pollution, especially fine particulate matter (PM2.5), may act as an environmental trigger for immune dysfunction. CanPath, Canada’s largest population health study, provides researchers with the data needed to examine these links in depth. How air pollution affects the immune system and autoimmune disease Air pollutants include PM2.5, nitrogen dioxide (NO2), ozone, and other entities. PM2.5 can enter the bloodstream, triggering systemic inflammation and immune dysregulation. While air pollution’s effects on respiratory conditions like asthma and lung cancer are well documented, its role in autoimmune diseases is a newer area of investigation. “One of the really cool things about these kinds of analyses was that it provided one of the first indications that air pollution may affect the immune system,” said Dr. Bernatsky. “Prior to these kinds of analyses, we had good data on what happens when you are exposed to PM2.5 in terms of asthma risk or lung cancer. That makes sense because you breathe in the air, and there’s a local effect. But this was one of the first analyses looking at a totally different kind of disease. It convinced people at Health Canada’s air health effects assessment division that, indeed, you can have health effects far beyond just the lung.” This growing body of research underscores the need for large-scale, longitudinal data to better understand the full spectrum of air pollution’s impact on immune-mediated conditions like rheumatoid arthritis and systemic lupus. CanPath’s role in advancing rheumatic disease research Arthritis data resources in CanPath: Biosamples, genotyping, and self-reported diagnoses for osteoarthritis, rheumatoid arthritis, and other forms CanPath’s large-scale, longitudinal dataset is an invaluable resource for researchers undertaking air pollution and autoimmune disease research. By linking environmental exposure data to genetic, lifestyle, and health information, CanPath enables scientists to explore how air pollution contributes to immune-mediated diseases over time. “CanPath serum samples and data were extremely helpful,” Dr. Bernatsky emphasized. “In fact, I just don’t see any way we could have done what we did without CanPath.”  Dr. Trevor Dummer, an expert in environmental health, reflected on the study’s evolution and its potential for continued discoveries: “It’s nice to see some of those results because I can think back to many, many years ago. You know, CanPath has been going for 15 years. Now it’s a considerable amount of time. I recall the early collaboration, so it’s great to see the fruits of all of those labours.” This extensive dataset allows researchers to track patterns over time, assessing how long-term exposure to air pollution affects disease development and progression. Implications for future research and public health The insights gained from CanPath’s data have the potential to: Inform air quality policies and environmental regulations Improve public health strategies for reducing autoimmune disease risks Enlighten scientific, patient and physician groups regarding immune-mediated disease etiology As air pollution remains a global concern, leveraging large-scale datasets will be key to understanding and mitigating its impact. Researchers can utilize CanPath data linked with environmental exposure data from the Canadian Urban Environmental Health Research Consortium (CANUE) to investigate immune-mediated diseases and the environment. Explore available datasets and application processes on the CanPath Portal By continuing to explore how pollution influences immune-mediated disease, researchers can also help shape policies and interventions that protect both individual and population health. For those looking to advance this work, CanPath data is invaluable for uncovering new insights in environmental and autoimmune disease research.

Synthetic Dataset Workshop (In-Person in Toronto)

Synthetic Dataset Workshop (In-Person in Toronto) Date: June 24, 2025 Time: 9:00 am- 4:30pm Location: Centre for Research and Innovation Support Register for the workshop Join us for an exclusive hands-on workshop on the CanPath Synthetic Dataset, designed for faculty, researchers, and trainees looking to explore Canada’s largest population health dataset. This workshop will introduce participants to Lifebit’s cloud-based platform and provide practical training on analyzing synthetic health data. What is the CanPath Synthetic Dataset? The CanPath Synthetic Dataset is a versatile resource designed for research, education, and practical applications. It was manipulated to mimic CanPath’s nationally harmonized data but does not include or reveal actual data of any CanPath participants. Interested in exploring the data? Check out the CanPath Data Dictionary. What is the Trusted Research Environment? The Trusted Research Environment (TRE) is a secure, cloud-based platform where researchers can access and analyze CanPath data without downloading it to their local machines. The TRE ensures data privacy and security, providing a controlled environment for conducting research while offering powerful tools for analysis. Participants in this workshop will learn how to navigate and use the TRE efficiently. Lifebit, CanPath and AWS have collaborated to bring this platform to life. Who should attend? This workshop is open to: Faculty/staff using the dataset for education (e.g., incorporating it into a course assignment). Faculty/staff using the dataset for training purposes (e.g., teaching trainees how to analyze population health data or preparing to apply for real CanPath data access). Trainees (e.g., postdoctoral fellows, graduate students, undergraduate students) interested in learning how to work with CanPath data. Learning objectives By the end of the workshop, participants will: Navigate and analyze the CanPath Synthetic Dataset using the Lifebit cloud-based platform. Work with pre-created analytical pipelines in R and Python (basic familiarity required). Understand how to bring in additional data and use platform tools such as the Cohort Browser, Airlock, and Data Factory. Gain insights from real-world case studies and demonstrations from CanPath experts. Connect with fellow researchers, instructors, and clinician scientists to foster future collaborations. Agenda The final agenda will be sent to attendees prior to the event. Time Session 9:00 AM Introduction to CanPath, Lifebit, staff and attendees 9:30 AM Training on the Lifebit platform and guided exercise 11:00 AM Coffee Break 11:15 AM Demonstration and case studies with CanPath data 12:00 PM Lunch Break 1:00 PM Hands-on analyses in the platform 2:30 PM Discussion: key learnings and future data strategy 3:30 PM Snacks and networking reception Additional support Need extra help? Attendees can attend Office Hours to get one-on-one support from Lifebit and CanPath experts. Participants can book sessions for personalized assistance. The location, date, and time will be announced soon. How to apply Participants must fill out an application to be considered. Applications are accepted on a rolling basis. Initial deadline: March 28 Space is limited! Apply early for the best chance of securing a spot.

The Government of Canada highlights progress on breast cancer screening research and implementation in Canada

News release Ottawa, Ontario | Public Health Agency of Canada Breast cancer is one of the most common forms of cancer and the second leading cause of cancer-related deaths among women. One in eight women in Canada is expected to be diagnosed with breast cancer in their lifetime. Raising awareness of breast cancer screening, which aims to detect cancer at an earlier, more treatable stage, is a priority for the Government of Canada. The Government of Canada is committed to supporting the health of women by addressing knowledge gaps in breast cancer screening and prevention. The Public Health Agency of Canada (PHAC), in collaboration with federal, provincial and territorial experts and stakeholders, hosted the event Closing the Gap: Action for Equity in Breast Cancer Screening. This event discussed improving accessibility and inclusivity in breast cancer screening, especially for underserved populations. Participants shared lessons learned and best practices that will be compiled into a resource guide that will be shared broadly across all jurisdictions to help improve equitable implementation of breast cancer screening in Canada. PHAC is working closely with Statistics Canada to conduct analyses of national cancer trends, including examining differences in breast cancer rates based on where people live, their age and ethnicity. This will support informed and data driven breast cancer screening policy. The Canadian Institutes of Health Research (CIHR) and partners have developed a multi-disciplinary roadmap that identifies research gaps for breast cancer screening and provides recommendations to guide future research activities in Canada. The roadmap summarizes what was heard from partners alongside key research areas and strategies to support breast cancer research in Canada. The Government of Canada is also working directly with our partners, like the Canadian Partnership for Tomorrow’s Health and the Canadian Cancer Society, to generate better data to inform breast cancer screening practices and raise awareness of its importance in Canada. Together, these initiatives support collaborative and scientific research, data collection, and public health guidance for breast cancer screening in Canada. Quotes “I would like to thank our partners and stakeholders for their commitment to overcome barriers and improve access to breast cancer screening in Canada. Awareness and access to breast cancer screening will make life changing differences for the health of Canadians.” The Honourable Mark Holland Minister of Health “Breast cancer touches the lives of so many, either through a personal diagnosis or that of a loved one. Through this work and the dedication of our partners, we are taking important steps to safeguard women’s physical and mental health.” The Honourable Ya’ara Saks Minister of Mental Health and Addictions and Associate Minister of Health Quick facts Breast cancer is the second most common cancer in women living in Canada, after non-melanoma skin cancer. While it can also be found in men, male breast cancer is a very rare occurrence. Breast cancer screening is used to detect cancer in people who do not have any signs or symptoms. This differs from diagnostic testing, which is used when someone does have signs or symptoms (e.g., a lump). The Government of Canada recognizes and respects that each province and territory has unique needs and different approaches to breast cancer screening. Provincial and territorial governments are responsible for diagnosis, treatment, services, programming and education. Associated links Canadian Cancer Society – Get your mammogram Canadian Partnership For Tomorrow’s Health Government of Canada invests in breast cancer research and public awareness Contacts Matthew Kronberg Press Secretary Office of the Honourable Mark Holland Minister of Health 343-552-5654 Callum Haney Press Secretary Office of the Honourable Ya’ara Saks Minister of Mental Health and Addictions and Associate Minister of Health 343-576-4407 Media Relations Health Canada 613-957-2983 media@hc-sc.gc.ca Public Inquiries 613-957-2991 1-866-225-0709

Upcoming Webinar – CanPath’s Genomic Landscape

Webinar: CanPath’s genomic data landscape: Insights from Ontario and Quebec Canada’s largest genomic data resource just got bigger … how will you use it? ?? CanPath now offers even more genotyping data from the Ontario Health Study (OHS) and CARTaGENE (Quebec), creating new opportunities to explore genetic ancestry, disease risk, and innovative research approaches. Join Dr. Philip Awadalla and Dr. Guillaume Lettre on Tuesday, March 2, at 11:00 AM EDT as they describe: Ontario’s latest genotyping data & research applications Genetic ancestry, the French Canadian founder effect & whole genome sequencing Emerging tools like liquid biopsy, cell-free DNA & single-cell studies Registration: https://bit.ly/41mOPq1

Webinar – Understanding the connections between air pollution and rheumatic disease

Join us for an upcoming CanPath webinar that considers the connections between air pollution and rheumatic disease. February 20, 2025   ~   12pmEST/1pmAST Registration: https://bit.ly/40YZNBx About the webinar Join Dr. Sasha Bernatsky, a leading researcher in rheumatic disease and environmental health, as she delves into how environmental exposures impact autoimmunity and inflammation. Drawing on her extensive work with CanPath, Dr. Bernatsky has demonstrated potential associations between air pollutants, including PM2.5, and autoimmunity and rheumatic diseases. In this session, Dr. Bernatsky will also preview her new research on the impact of wildfire smoke and temperature extremes on rheumatic diseases in Canada, supported by recent CIHR funding. Researchers interested in environmental health, autoimmune diseases, and leveraging population-based data for innovative studies won’t want to miss this opportunity to gain valuable insights and explore future directions in the field. About the presenter Dr. Sasha Bernatsky Sasha Bernatsky, MD PhD, is a rheumatologist, a James McGill Professor of Medicine at McGill University and a Senior Scientist of the Centre for Health Outcomes Research at the Research Institute of the McGill University Health Centre.  Dr. Bernatsky is also affiliated with the McGill Environmental Epidemiology Research Group, a network with expertise in pharmacology/toxicology, and environmental sciences. She is a member of the Canadian Urban Environmental Health Research Consortium (CANUE), the Systemic Lupus International Collaborating Clinics (SLICC), and the Canadian Network for Improved Outcomes in SLE (CaNIOS). Her research focuses mainly on outcomes in rheumatic diseases, pharmacoepidemiology, and air pollution’s effects on health.

Quality of Non‐Surgical and Non‐Pharmacological Knee Osteoarthritis Care in the Maritimes

Authors: Aleksandra Budarick, Cheryl Hubley-Kozey, Linda Li, Olga Theou, William Stanish Journal: Musculoskeletal Care Objectives: To evaluate the quality and types of care individuals with mild‐to‐moderate knee osteoarthritis receive in the Canadian Maritime provinces, and determine associations with demographic, social, and patient‐reported factors. Methods: Individuals with knee osteoarthritis were invited to complete a healthcare quality survey based on the British Columbia Osteoarthritis (BC OA) survey. The cross‐sectional descriptive observational survey assessed four healthcare quality indicators: advice to exercise, advice to lose weight, assessment of ambulatory function, and assessment of non‐ambulatory function. Pass‐rates were calculated overall and for each quality indicator. Binary logistic regressions determined associations between quality indicators and demographic, social, and patient‐reported outcomes. Patient‐reported use of exercise and diet as arthritis treatments were added to the quality indicator eligibility criteria as a sensitivity analysis. Results: Participants (n = 241) had a mean age of 67 (7) years, body mass index of 30.7 (7.5) kg/m2 and were 77% female. The overall pass rate was 42.9% using the BC OA criteria, and 49.3% in the sensitivity analysis. Individual quality indicator pass‐rates ranged from 4.3% for non‐ambulatory function to 85.7% for ambulatory function assessments. The sensitivity analysis increased pass‐rates for advice to exercise (61.9%–69.3%) and advice to lose weight (27.9%–35.1%). Pass‐rates were not driven by demographic, social, or patient‐reported factors. Conclusions: Over half of individuals with mild‐to‐moderate knee osteoarthritis did not receive recommended core treatments in the Maritimes, highlighting a need to improve care for this patient group. Quality indicators should be routinely evaluated to determine whether clinical care aligns with best practice guidelines. doi: 10.1002/msc.70047

New Article – Quality of Non-Surgical and Non-Pharmacological Knee Osteoarthritis Care in the Maritimes

Congratulations to Aleksandra Budarick, Dr. Cheryl Hubley-Kozey, Dr. Rebecca Moyer and team on their new article, “Quality of Non-Surgical and Non-Pharmacological Knee Osteoarthritis Care in the Maritimes.” Participants with osteoarthritis from Atlantic PATH were invited to participate in an ancillary study about the Current Management and Health Care Quality for Patients with Knee and Hip Osteoarthritis. Over half of individuals with mild-to-moderate knee osteoarthritis did not receive recommended core treatments in the Maritimes, highlighting a need to improve care for this patient group.

Global Biobank Meta-Analysis Initiative: How CanPath is Powering Genetic Discovery Across Human Disease

The Global Biobank Meta-analysis Initiative (GBMI) unites 24 biobanks, including CanPath and its regional cohorts, with data from over 2.2 million people, to power global genetic discovery. By integrating diverse genetic info, GBMI improves disease risk prediction, advances personalized medicine, and boosts discoveries. CanPath contributes Canadian data, adding diversity and impact! Together, they’ve harmonized data, improved data on 14 diseases, and accelerated drug target discovery. The future? More inclusivity, better data sharing, and deeper disease insights.

CIHR Team Grants: Bringing Biology to Cancer Prevention

Team Grants — Bringing Biology to Cancer Prevention  This opportunity is led by the CIHR Institute of Cancer Research (CIHR-ICR) in collaboration with the CIHR Institutes of: Aging (CIHR-IA), Gender and Health (CIHR-IGH), Nutrition, Metabolism and Diabetes (CIHR-INMD), Population and Public Health (CIHR-IPPH), and in partnership with the BioCanRx, Canadian Cancer Society (CCS), Cancer Research Society (CRS), Japan Agency for Medical Research and Development (AMED) – Adopting Sustainable Partnerships for Innovative Research Ecosystem (ASPIRE), and the Terry Fox Research Institute (TFRI). This funding opportunity aims to unite interdisciplinary research teams to advance the biological and mechanistic understanding of cancer etiology, genesis, and risk to identify new targets and approaches for cancer prevention, risk reduction and early detection. CanPath and Atlantic PATH can provide letters of support for applicants using our data and biological samples. Registration deadline: April 1, 2025 Application deadline: June 19, 2025 Additional details: https://bit.ly/3PtR8SC Upcoming webinars: January 29, 12:30-2:00 PM ET | Register here. February 5, 12:30-2:00 PM ET | Register here